Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 15,200 shares, a drop of 14.1% from the September 30th total of 17,700 shares. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.5% of the shares of the company are sold short.
NASDAQ:EYEG traded up $0.39 during mid-day trading on Friday, reaching $4.69. The stock had a trading volume of 33,300 shares, compared to its average volume of 25,303. Eyegate Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $8.85. The stock has a market capitalization of $15.64 million, a PE ratio of -1.04 and a beta of 2.16. The stock has a 50-day simple moving average of $3.56 and a two-hundred day simple moving average of $1.44.
In other news, major shareholder Armistice Capital Master Fund acquired 605,001 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average cost of $3.12 per share, with a total value of $1,887,603.12. 47.50% of the stock is currently owned by company insiders.
Separately, ValuEngine cut shares of Eyegate Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday.
Eyegate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Recommended Story: What is the QQQ ETF?
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.